2026-04-29T04:09:49Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/183782024-11-28T15:17:28Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Teuwen, Laure-Anne author De Rooij, Laura P. M. H. author Cuypers, Anne author Rohlenova, Katerina author Dumas, Sébastien J. author García-Caballero, Melissa author Meta, Elda author Amersfoort, Jacob author Taverna, Federico author Becker, Lisa M. author Veiga, Nuphar author Cantelmo, Anna Rita author Geldhof, Vincent author Conchinha, Nadine V. author Kalucka, Joanna author Treps, Lucas author Conradi, Lena-Christin author Khan, Shawez author Karakach, Tobias K. author Soenen, Stefaan author Vinckier, Stefan author Schoonjans, Luc author Eelen, Guy author Van Laere, Steven author Dewerchin, Mieke author Dirix, Luc author Mazzone, Massimiliano author Luo, Yonglun author Vermeulen, Peter author Carmeliet, Peter authoraffiliation [Teuwen,LA; De Roji,PMH; Cuypers,A; Rohlenova,A; Dumas,SH; García-Caballero,M; Meta,E; Amersfoort,J; Taverna,F; Becker,LM; Veiga,N; Cantelmo,AR; Geldhof,V; Conchinha,NV; Kalucka,J; Treps,L; Conradi,LC; Khan,S; Karakach,TK; Vinckier,S; Schoonjans,L; Eelen,G; Dewerchin,M; Carmeliet,P] Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. [Teuwen,LA; Van Laere,S; Dirix,L; Vermeulen,P] Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium. [Teuwen,LA; Van Laere,S; Dirix,L; Vermeulen,P] Center for Oncological Research, University of Antwerp, Antwerp, Belgium. [Soenen,S] NanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. [Schoonjans,L; Carmeliet,P] State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, P.R. China. [Mazzone,M] Laboratory of Tumor Inflammation and Angiogenesis, CCB, VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. [Luo,Y] Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Luo,Y] Lars Bolund Institute of Regenerative Medicine, BGI-Qingdao, Qingdao, P.R. China. [Luo,Y] BGI-Shenzhen, Shenzhen, China. [Luo,Y] China National GeneBank, BGI-Shenzhen, Shenzhen, P.R. China. [Carmeliet,P] Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Rohlenova,K] Institute of Biotechnology of the Czech Academy of Sciences, Praha – za´ pad, Central Bohemia, Czechia. [García-Caballero,M] Department of Molecular Biology and Biochemistry, Faculty of Sciences, and IBIMA (Biomedical Research Institute of Málaga), University of Málaga, Andalucía Tech, Málaga, Spain. [Cantelmo,AR] Laboratory of Cell Physiology, Lille University, Villeneuve d’Ascq, France. [Kalucka,J] Aarhus Institute of Advanced Studies (AIAS); Department of Biomedicine, Aarhus University, Aarhus, Denmark. [Conradi,LC] Clinic of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. [Khan,S] National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. [Karakach,TK] Bioinformatics Core Laboratory, Children’s Hospital Research Institute of Manitoba, Winnipeg, Canada. [Karakach,TK] Rady Faculty of Health Sciences, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba Canada. 2024-02-19T15:29:14Z 2024-02-19T15:29:14Z 2021-06-15 http://hdl.handle.net/10668/3614 http://hdl.handle.net/20.500.12105/18378 34133923 10.1016/j.celrep.2021.109253 2211-1247 Cell Reports Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent. eng Tumor vessel co-option Tumor angiogenesis Anti-angiogenic therapy Metastasis Resistance Single-cell RNA sequencing Endothelial cells Pericytes Macrophages Cancer cells Inductores de la angiogénesis Metástasis de la neoplasia Células endoteliales Pericitos Macrófagos Tumor vessel co-option probed by single-cell analysis research article